Search research articles
Contact Us
Filters
Showing results (131-140 of 173) with videos related to
Page
of 18
Sort By:
Journal of Translational Medicine
|
July 27, 2011
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Charles S Harmon, Samuel E DePrimo, Eric Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients
Jérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Oncotarget
|
November 12, 2016
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Maria E Riveiro, Lucile Astorgues-Xerri, Ramiro Vazquez, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
The Oncologist
|
April 15, 2011
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities
Christian Kollmannsberger, Georg Bjarnason, Patrick Burnett, et al.
The Lancet. Oncology
|
July 10, 2009
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre, Eric Raymond, Eveline Boucher, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 173) with videos related to
Sort By:
Page
of 18
Journal of Translational Medicine
|
July 27, 2011
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib
Charles S Harmon, Samuel E DePrimo, Eric Raymond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
Anne O'Donnell, Sandrine Faivre, Howard A Burris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 27, 2004
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients
Jérôme Alexandre, Eric Raymond, Mahmoud Ould Kaci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Plos One
|
June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
Oncotarget
|
November 12, 2016
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Maria E Riveiro, Lucile Astorgues-Xerri, Ramiro Vazquez, et al.
Plos One
|
March 27, 2020
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.
The Oncologist
|
April 15, 2011
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities
Christian Kollmannsberger, Georg Bjarnason, Patrick Burnett, et al.
The Lancet. Oncology
|
July 10, 2009
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
Sandrine Faivre, Eric Raymond, Eveline Boucher, et al.
Investigational New Drugs
|
September 18, 2015
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors
Sandrine J Faivre, Anthony J Olszanski, Karin Weigang-Köhler, et al.
Page
of 18